Piper Sandler Lowers Humacyte (NASDAQ:HUMA) Price Target to $3.00

Humacyte (NASDAQ:HUMAGet Free Report) had its target price dropped by stock analysts at Piper Sandler from $3.50 to $3.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 27.66% from the company’s previous close.

A number of other research firms also recently commented on HUMA. Benchmark reiterated a “buy” rating and set a $16.00 price objective on shares of Humacyte in a research note on Tuesday, August 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price objective on shares of Humacyte in a research note on Thursday, September 21st.

Get Our Latest Analysis on Humacyte

Humacyte Price Performance

Humacyte stock opened at $2.35 on Friday. The firm has a market capitalization of $243.06 million, a P/E ratio of -2.70 and a beta of 1.22. The firm has a fifty day moving average of $2.79 and a 200-day moving average of $3.25. The company has a quick ratio of 10.59, a current ratio of 10.59 and a debt-to-equity ratio of 0.29. Humacyte has a 52-week low of $1.96 and a 52-week high of $5.60.

Humacyte (NASDAQ:HUMAGet Free Report) last announced its earnings results on Monday, August 14th. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). During the same quarter in the previous year, the company earned ($0.19) earnings per share. As a group, analysts predict that Humacyte will post -0.93 EPS for the current year.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 626,979 shares of the stock in a transaction on Friday, August 18th. The shares were sold at an average price of $3.57, for a total transaction of $2,238,315.03. Following the sale, the director now directly owns 8,793,583 shares of the company’s stock, valued at $31,393,091.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Humacyte news, CEO Laura E. Niklason sold 570,174 shares of the firm’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $3.68, for a total transaction of $2,098,240.32. Following the transaction, the chief executive officer now owns 9,420,562 shares of the company’s stock, valued at approximately $34,667,668.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brady W. Dougan sold 626,979 shares of the firm’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $3.57, for a total transaction of $2,238,315.03. Following the transaction, the director now directly owns 8,793,583 shares in the company, valued at approximately $31,393,091.31. The disclosure for this sale can be found here. Insiders have sold 3,799,596 shares of company stock worth $11,938,837 in the last ninety days. 23.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Humacyte

Large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Humacyte by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 458,463 shares of the company’s stock valued at $1,343,000 after purchasing an additional 58,920 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of Humacyte by 126.1% during the 3rd quarter. Private Advisor Group LLC now owns 94,980 shares of the company’s stock valued at $278,000 after purchasing an additional 52,980 shares in the last quarter. Private Management Group Inc. bought a new position in shares of Humacyte during the 3rd quarter valued at about $45,000. Commonwealth Equity Services LLC bought a new position in shares of Humacyte during the 3rd quarter valued at about $37,000. Finally, Powell Investment Advisors LLC bought a new position in shares of Humacyte during the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 27.36% of the company’s stock.

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Further Reading

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.